Moderna Dives 11% After RSV Vaccine Proves Less Effective Than Pfizer, GSK Shots

 Moderna (MRNA) stock tumbled Wednesday after the company said its newly approved RSV vaccine was only about 50% effective after 18 months — paling in comparison to rivals from Pfizer (PFE) and GSK (GSK).

Respiratory syncytial virus, or RSV, causes coldlike symptoms in most people. But it can be serious or deadly in newborns and older adults.

After 18 months, Moderna's RSV vaccine proved 49.9% to 50.3% effective against multiple symptoms of lower respiratory tract disease. In comparison, GSK said its vaccine, Arexvy, was 78.6% effective against severe RSV after two years. Similarly, Pfizer's Abrysvo was 77.8% effective midway through a second season on the market.

Moderna stock toppled 11% to 122.45 on today's stock market. Pfizer stock also fell more than 2% to 27.42, while GSK stock skidded 3.6% to 38.87.

https://www.investors.com/news/technology/moderna-stock-rsv-vaccine-mresvia-18-month-effectiveness-pfizer-gsk-arexvy-abrysvo/